Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains.
3-Deazaadenosine (DZA), 3-deaza-(+/-)-aristeromycin (DZAri), and 3-deazaneplanocin A (DZNep) are powerful modulators of cellular processes. When tested against H9 cells infected acutely with two different strains of human immunodeficiency virus 1 (HIV-1) and in the chronically infected monocytoid cell lines U1 and THP-1, the 3-deazanucleosides caused a marked reduction in p24 antigen production. Similar reductions in p24 antigen were seen in phytohemagglutinin-stimulated peripheral blood mononuclear cells infected with clinical HIV-1 isolates. Strikingly, in comparing the therapeutic indices between the paired pre- and post-3'-azido-3'-deoxythymidine (AZT) treatment HIV-1 isolates, DZNep and neplanocin A showed an increase of 3- to 18-fold in their potency against AZT-resistant HIV-1 isolates. In H9 cells treated with DZNep and DZAri, the formation of triphosphate nucleotides of DZNep and DZAri was observed. The mode of action of DZNep and DZAri appears complex, at least in part, at the level of infectivity as shown by decreases in syncytia formation in HIV-1-infected H9 cells and at the level of transcription as both drugs inhibited the expression of basal or tat-induced HIV-1 long terminal repeat chloramphenicol acetyltransferase activity in stably transfected cell lines. Since DZNep induced in H9 cells a rapid expression of nuclear binding factors that recognize the AP-1 transcription site, the anti-HIV-1 activity of the DZA analogs could partly be the induction of critical factors in the host cells. Thus, the 3-deazanucleoside drugs belong to an unusual class of anti-HIV-1 drugs, which may have therapeutic potential, in particular against AZT-resistant strains.
Mayers
D L
DL
Walter Reed Army Institute of Research, Washington, DC 20307-5100.
Mikovits
J A
JA
Joshi
B
B
Hewlett
I K
IK
Estrada
J S
JS
Wolfe
A D
AD
Garcia
G E
GE
Doctor
B P
BP
Burke
D S
DS
Gordon
R K
RK
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood; D000998:Antiviral Agents / Q000494:pharmacology* / Q000633:toxicity; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004352:Drug Resistance, Microbial; D016655:HIV Core Protein p24 / Q000032:analysis / Q000096:biosynthesis; D018023:HIV Seronegativity; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009000:Monocytes / Q000187:drug effects / Q000473:pathology / Q000821:virology; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014157:Transcription Factors / Q000032:analysis / Q000096:biosynthesis; D014372:Tubercidin / Q000494:pharmacology* / Q000633:toxicity; D015215:Zidovudine / Q000494:pharmacology*
D000998:Antiviral Agents; D016655:HIV Core Protein p24; D014157:Transcription Factors; C018258:3-deazaadenosine; D015215:Zidovudine; D014372:Tubercidin